arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Pulmatrix, Inc.

PULM
$1.66 ▼ -0.01 (-0.60%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
54 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

Pulmatrix, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.1M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -28.4%
FCF / Share $-0.29
Trailing P/E
Price / Book 1.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

54-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.00K
↓ -99.9%
Net Income Profit after all expenses
$-1.17M
↑ +35.2%
Operating Margin Operating profit as % of sales
-380.2%
↓ -3095.4%
FCF / Share Free cash flow per share
$-0.29
↑ +41.1%
Long-Term Debt Long-term obligations
$1.80M
↓ -28.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
6
Cash Quality
68

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 54 quarters